Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(5):614–621. doi: 10.1038/bjc.1997.434

Production and characterization of a recombinant anti-MUC1 scFv reactive with human carcinomas.

G Denton 1, M Sekowski 1, D I Spencer 1, O D Hughes 1, A Murray 1, H Denley 1, S J Tendler 1, M R Price 1
PMCID: PMC2228010  PMID: 9303360

Abstract

Recombinant single-chain fragments (scFv) of the murine anti-MUC1 monoclonal antibody C595 have been produced using the original hybridoma cells as a source of variable heavy (V(H))- and variable light (V(L))-chain-encoding antibody genes. The use of the polymerase chain reaction (PCR), bacteriophage (phage) display technology and gene expression systems in E. coli has led to the production of soluble C595 scFv. The scFv has been purified from the bacterial supernatant by peptide epitope affinity chromatography, leading to the recovery of immunoreactive C595 scFv, which was similar in activity to the C595 parent antibody. Analysis by DNA sequencing, SDS-PAGE and Western blotting has demonstrated the integrity of the scFv, while ELISA, FACScan analysis, fluorescence quenching, quantitative immunoreactivity experiments and immunohistochemistry confirm that the activity of the scFv compares favourably with that of the parent antibody. The retention of binding activity to MUC1 antigen on human bladder and breast carcinoma tissue specimens illustrates the potential application of this novel product as an immunodiagnostic and immunotherapeutic reagent.

Full text

PDF
614

Images in this article

617Figure 1
on p.617
617Figure 2
on p.617
618Figure 3
on p.618
619Figure 7
on p.619

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berruti A., Tampellini M., Torta M., Buniva T., Gorzegno G., Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer. 1994;30A(14):2082–2084. doi: 10.1016/0959-8049(94)00356-a. [DOI] [PubMed] [Google Scholar]
  2. Denton G., Davies G. M., Scanlon M. J., Tendler S. J., Price M. R. Primary sequence determination and molecular modelling of the variable region of an antiMUC1 mucin monoclonal antibody. Eur J Cancer. 1995;31A(2):214–221. doi: 10.1016/0959-8049(94)00431-4. [DOI] [PubMed] [Google Scholar]
  3. Denton Graeme, Price Michael R. Immune Responses to the MUC1 Mucin. Pathol Oncol Res. 1995;1(1):27–31. doi: 10.1007/BF02893580. [DOI] [PubMed] [Google Scholar]
  4. Dixon A. R., Price M. R., Hand C. W., Sibley P. E., Selby C., Blamey R. W. Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer--a comparison with CA15.3. Br J Cancer. 1993 Nov;68(5):947–949. doi: 10.1038/bjc.1993.459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Doménech N., Henderson R. A., Finn O. J. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol. 1995 Nov 15;155(10):4766–4774. [PubMed] [Google Scholar]
  6. Gendler S. J., Spicer A. P., Lalani E. N., Duhig T., Peat N., Burchell J., Pemberton L., Boshell M., Taylor-Papadimitriou J. Structure and biology of a carcinoma-associated mucin, MUC1. Am Rev Respir Dis. 1991 Sep;144(3 Pt 2):S42–S47. doi: 10.1164/ajrccm/144.3_pt_2.S42. [DOI] [PubMed] [Google Scholar]
  7. Gendler S., Taylor-Papadimitriou J., Duhig T., Rothbard J., Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem. 1988 Sep 15;263(26):12820–12823. [PubMed] [Google Scholar]
  8. Hudecz F., Price M. R. Monoclonal antibody binding to peptide epitopes conjugated to synthetic branched chain polypeptide carriers. Influence of the carrier upon antibody recognition. J Immunol Methods. 1992 Mar 4;147(2):201–210. doi: 10.1016/s0022-1759(12)80009-3. [DOI] [PubMed] [Google Scholar]
  9. Hughes O. D., Bishop M. C., Perkins A. C., Frier M., Price M. R., Denton G., Smith A., Rutherford R., Schubiger P. A. Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer. Eur J Nucl Med. 1997 Apr;24(4):439–443. doi: 10.1007/BF00881818. [DOI] [PubMed] [Google Scholar]
  10. Jerome K. R., Barnd D. L., Bendt K. M., Boyer C. M., Taylor-Papadimitriou J., McKenzie I. F., Bast R. C., Jr, Finn O. J. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 1991 Jun 1;51(11):2908–2916. [PubMed] [Google Scholar]
  11. Kotera Y., Fontenot J. D., Pecher G., Metzgar R. S., Finn O. J. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 1994 Jun 1;54(11):2856–2860. [PubMed] [Google Scholar]
  12. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  13. Martoni A., Zamagni C., Bellanova B., Zanichelli L., Vecchi F., Cacciari N., Strocchi E., Pannuti F. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur J Cancer. 1995 Sep;31A(10):1615–1621. doi: 10.1016/0959-8049(95)00340-o. [DOI] [PubMed] [Google Scholar]
  14. McCafferty J., Griffiths A. D., Winter G., Chiswell D. J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990 Dec 6;348(6301):552–554. doi: 10.1038/348552a0. [DOI] [PubMed] [Google Scholar]
  15. Perkins A. C., Symonds I. M., Pimm M. V., Price M. R., Wastie M. L., Symonds E. M. Immunoscintigraphy of ovarian carcinoma using a monoclonal antibody (111In-NCRC48) defining a polymorphic epithelial mucin (PEM) epitope. Nucl Med Commun. 1993 Jul;14(7):578–586. doi: 10.1097/00006231-199307000-00011. [DOI] [PubMed] [Google Scholar]
  16. Price M. R., Briggs S., Scanlon M. J., Tendler S. J., Sibley P. E., Hand C. W. The mucin antigens: what are we measuring? Dis Markers. 1991 May-Aug;9(3-4):205–212. [PubMed] [Google Scholar]
  17. Price M. R., Pugh J. A., Hudecz F., Griffiths W., Jacobs E., Symonds I. M., Clarke A. J., Chan W. C., Baldwin R. W. C595--a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer. 1990 May;61(5):681–686. doi: 10.1038/bjc.1990.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Price M. R., Sekowski M., Tendler S. J. Purification of anti-epithelial mucin monoclonal antibodies by epitope affinity chromatography. J Immunol Methods. 1991 May 17;139(1):83–90. doi: 10.1016/0022-1759(91)90354-i. [DOI] [PubMed] [Google Scholar]
  19. Rughetti A., Turchi V., Ghetti C. A., Scambia G., Panici P. B., Roncucci G., Mancuso S., Frati L., Nuti M. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res. 1993 Jun 1;53(11):2457–2459. [PubMed] [Google Scholar]
  20. Schmid I., Schmid P., Giorgi J. V. Conversion of logarithmic channel numbers into relative linear fluorescence intensity. Cytometry. 1988 Nov;9(6):533–538. doi: 10.1002/cyto.990090605. [DOI] [PubMed] [Google Scholar]
  21. Winter G., Milstein C. Man-made antibodies. Nature. 1991 Jan 24;349(6307):293–299. doi: 10.1038/349293a0. [DOI] [PubMed] [Google Scholar]
  22. Yokota T., Milenic D. E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992 Jun 15;52(12):3402–3408. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES